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Preface 
 
 
Undine, painted 1872 by John William Waterhouse (photo from Wikipedia) 
The water nymph Undine is a mythological figure of European tradition. According 
to one version of the myth, Undine, having been betrayed by her mortal husband, 
took from him all automatic functions, requiring him to remember to breathe. When 
he finally fell asleep, he died [1]. 
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Abstract 
Background/purpose: Chronic hypercapnic respiratory failure (CHRF) is associated 
with increased mortality in patients with chronic obstructive pulmonary disease 
(COPD), and sleep hypoventilation (SH) has been proposed as a possible predictor 
for CHRF in COPD. SH was previously found in COPD patients with CHRF using 
long term oxygen therapy (LTOT). However, SH in normocapnic, non-LTOT 
subjects have not been described. More than half of COPD patients have difficulties 
in initiating or maintaining sleep or are excessively sleepy at daytime. Hypnotics and 
alcohol are often used although both are known to depress the respiratory drive to 
breathe, and little is known regarding SH due to these agents. We have explored the 
associations between sleep architecture and nocturnal and daytime blood gases in 
stable COPD, both in spontaneous sleep and during sleep influenced by alcohol or the 
hypnotic zopiclone.  
Material/methods: Paper I is an observational sleep study in a pulmonary 
rehabilitation hospital of 100 (39 male) stable COPD inpatients, mean FEV1 1.1 L 
(42% of predicted), mean age 64 years, using polysomnography with transcutaneous 
measurement of carbon dioxide pressure increase (∆ptcCO2). Paper II and paper III 
presents data from interventional sleep recordings from 26 (9 male) and 31 (10 male) 
of the same subjects described in paper I, influenced by 0.5 mg ethanol/kg 
bodyweight or a pill of 5 mg zopiclone, respectively. 
Results: SH in spontaneous sleep was found in 15%, and although most had CHRF, 
six subjects were daytime normocapnic. Alcohol induced a mean (95% confidence 
interval) increase in the ∆ptcCO2 during sleep of only 0.1 kPa (0.0-0.2, p=0.047) with 
no significant increase in the frequency of SH, whereas zopiclone increased the mean 
(SD) ∆ptcCO2 with 0.23 (0.33) kPa, and the frequency of SH from 19% to 42% 
(p=0.020). 
Conclusions/consequences: SH is found both in hypercapnic and normocapnic 
COPD subjects. Whether it is a real predictor of CHRF should be investigated by 
prospective case-control studies. A moderate dose of alcohol has only minor effects 
on breathing at sleep whereas zopiclone increases the frequency of SH in COPD. 
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1. Abbreviations 
   Diagnoses and therapy 
COPD Chronic Obstructive Pulmonary Disease  
OSA Obstructive Sleep Apnea 
CPAP Continuous Positive Airway Pressure 
IPR Inpatient Pulmonary Rehabilitation 
LTOT Long Term Oxygen Therapy 
NIV Non Invasive Ventilation 
    
Function and classification 
FEV1 Forced Expiratory Volume first second (by spirometry) 
FVC Forced Vital Capacity (by spirometry) 
TLC Total Lung Capacity 
RV Residual Volume of the lung 
DLCO Diffusing capacity of the Lung for Carbon monOxide 
BMI Body Mass Index (bodyweight/(height in meters) squared) 
6MWD Six Minute Walking Distance at pace decided by the patient 
MMRC Modified Medical Research Council questionnaire 
BODE Body mass index, airflow Obstruction, Dyspnea, Exercise (indicator of 
prognosis in COPD) 
GOLD Global initiative of chronic Obstructive Lung Disease 
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Gases and pressures 
CO2 carbon dioxide 
O2 Oxygen 
pO2 pressure of oxygen 
pCO2 pressure of carbon dioxide 
paCO2 arterial pressure of carbon dioxide 
petCO2 end tidal expiratory pressure of carbon dioxide 
ptcCO2 transcutaneous pressure of carbon dioxide 
ΔptcCO2 ptcCO2 increase from the pre sleep ptcCO2 
SaO2 arterial oxygen saturation 
SpO2 oxygen saturation measured by pulse oximeter 
kPa kilopascal (1 kPa = 7.50 mmHg) 
mmHg millimeters of mercury (1 mmHg = 0.133 kPa) 
 
Sleep 
AASM American Academy of Sleep Medicine 
AHI Apnea Hypopnea Index (number of events per hour of sleep) 
EEG ElectroEncephaloGraphic trace (of brain activity) 
EMG ElectroMyoGraphic trace (of muscle activity) 
EOG ElectroOculoGraphic trace (of eye muscle activity) 
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REM Rapid Eye Movement sleep 
NREM Non- Rapid Eye Movement sleep 
N0 awake after initial sleep onset  
N1 Subgroup of NREM, transition from wakefulness to sleep (EEG changing 
between alpha and theta waves) 
N2 Subgroup of NREM, intermediate sleep (theta wave EEG including sleep 
spindles and K-complexes) 
N3 Subgroup of NREM, deep sleep (≥ 20% delta (slow) wave activity in EEG) 
PG PolyGrapy (recording of airflow, respiratory movement in thorax and 
abdomen, position and oxygen saturation) 
PSG PolySomnoGraphy (recording of sleep, eye and leg movement, electric 
heart activity, airflow, respiratory movement in thorax and abdomen, 
position and oxygen saturation. In this study also including transcutaneous 
pressure of carbon dioxide) 
TST Total Sleep Time 
    
Hypoventilation 
CHRF Chronic Hypercapnic Respiratory Failure (defined as awake daytime seated 
paCO2 ≥ 6.3 kPa in stable phase of COPD) 
SH Sleep Hypoventilation (defined by the AASM as an increase from pre sleep 
paCO2 ≥ 1,3 kPa to > 6,7 kPa for ≥ 10 minutes sleep or an increase in 
paCO2 to > 7,3 kPa for ≥ 10 minutes sleep) 
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Statistics 
CI Confidence Interval (a range of good estimates of the true, unknown 
parameter) 
IQR InterQuartile Range (midspread measure of dispersion; IQR = 75%Quartile – 
25%Quartile) 
SD Standard Deviation (measure of dispersion; SD = the square root of the 
datasets' variance) 
p probability of finding the observed sample results, or "more extreme" 
results, when the null hypothesis is actually true (any value ≥ 1) 
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1 General introduction 
1.1 Background 
A great proportion of the inpatients at Glittreklinikken pulmonary hospital has COPD 
and many of them report low quality of sleep. The disease severity in these patients is 
quite diverse; the expiratory and static lung volumes differ considerably, some have 
respiratory failure with low arterial pressure of oxygen (paO2) and/or increased 
pressure of carbon dioxide (paCO2), some hypoventilate during sleep and some have 
frequent obstructive sleep apneas. Classification, treatment options and evaluation of 
prognosis in COPD is reasonably well established according to symptoms, 
spirometric parameters and daytime arterial blood gas pressures [2]. However, blood 
gas changes during sleep both in COPD patients and in normal individuals is sparsely 
investigated. As a physician at the hospital searching for diagnosis and treatment of 
sleep related breathing disturbances in my COPD patients, I encountered difficulties 
in interpreting the results from nocturnal pulse oximetry and transcutaneous 
measurements of carbon dioxide pressure (ptcCO2), realizing the need to determine 
whether the patient actually was asleep when these data were recorded. Furthermore, 
I was concerned about the possible risks of hypoventilation during sleep when these 
lung diseased patients were influenced by hypnotic medication, alcohol or 
supplementary oxygen; all agents commonly used by our patients and all known to 
somehow alter breathing [3-5]. Also, sudden death, probably by cardiac arrhythmias 
is common in COPD [6], and often occurs in the morning [7]. Thus, a study was 
initiated at Glittreklinikken, collecting arterial and venous blood samples, spirometry, 
static lung volume, Impulse Oscillometry and Negative Expiratory Pressure data, 24 
hour electrocardiographic recordings and polysomnography (PSG) including ptcCO2-
traces from stable COPD patients. This thesis presents the findings from spontaneous 
sleep as well as zopiclone (a hypnotic drug) and alcohol influenced sleep in relation 
to some of the data collected at daytime in these subjects. 
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1.2 Chronic Obstructive Pulmonary Disease (COPD) 
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
COPD is a common, treatable and preventable disease, characterized by persistent, 
usually progressive airflow limitations, with a chronic inflammatory response in the 
airways and lungs to noxious particles or gases [2]. Major symptoms are dyspnea, 
cough and sputum production. The airflow limitation is caused by a combination of 
small airway disease (obstructive bronchiolitis) and parenchymal destruction 
(emphysema), the relative contributions of which vary from person to person [2]. 
COPD is now considered the third leading cause of death worldwide [8], with a 
prevalence estimated to approximately 9-10 % in the adult population [9,10]. In 
Norway, one study reports a GOLD-defined COPD prevalence of 7 % [11].  
Comorbidities are often present and have a significant impact on the prognosis, with 
respiratory failure being considered the major cause of death in advanced COPD 
[12,13]. Chronic hypercapnia has previously been shown to predict increased 
mortality in COPD-patients [14], and in a recent prospective cohort study of 2,249 
patients with oxygen-dependent COPD, PaCO2 was an independent prognostic factor 
with a U-shaped association with mortality [15].  
Cigarette smoking is one of the most important causes; hence smoking cessation is 
the single most effective intervention to reduce the risk of developing COPD and to 
slow its progression [16]. Treatment of COPD includes bronchodilators, 
glucocorticoids, methylxanthines, phosphodiesterase-4 inhibitors, supplementary 
oxygen, vaccines, nutritional supplements, pulmonary rehabilitation, ventilator 
support and surgery [2]. 
 
1.3 Normal human sleep 
Sleep is a natural, periodically recurring state of inactivity, characterized by the loss 
of consciousness and reduced responsiveness to external stimuli. In contrast, 
wakefulness is the absence of sleep and is marked by consciousness, awareness and 
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activity [17]. The purpose of sleep is uncertain but it appears to be an active process 
of complex activity in the brain. 
1.3.1 Sleep stages and scoring 
Electro-encephalo/oculo/myo-graphic traces (EEG, EOG and EMG, respectively) 
differentiate wakefulness from sleep, as well as the two states within sleep; rapid-eye-
movement (REM) and non-rapid-eye-movement (NREM) sleep [18]. NREM sleep is 
subdivided in stages N1 (transition from wakefulness to sleep), N2 (intermediate 
sleep) and N3 (deep sleep) [19]. The individual is most easily awaken in stages N1 
and N2 compared to N3, the latter being necessary for restorative sleep, whereas in 
REM sleep episodic bursts of rapid eye movements are observed, skeletal muscles are 
atonic and dreaming is frequent. 
Historically, the stages of sleep according to EEG traces were first described by 
Loomis et al in 1937 [20], dividing sleep into 5 levels from wakefulness to deep 
sleep. In 1953 rapid eye movement (REM) sleep was discovered as distinct, thus 
sleep was reclassified by Dement and Kleitman into REM and 4 NREM stages [21]. 
Sleep scoring rules were standardized in 1968 by Rechtschaffen and Kyles in the 
"R&K sleep scoring manual" [18], whereas a major revision was published in 2007 
by the AASM commissioned Visual Scoring Task Force [19]. The most significant 
difference between the initial R&K versus the revised AASM scoring manual was the 
merging of the NREM stages S3 and S4 described in the R&K manual into one N3 
"slow wave sleep" stage in the AASM manual. 
1.3.2 Arousals   
An arousal is an abrupt change in the EEG-pattern typically as a shift from a deeper 
to a lighter NREM-stage, representing a short awakening without reaching 
consciousness. The role of arousals in normal sleep is a matter of debate, as it can be 
viewed both as a natural part of sleep homeostasis and as a defense mechanism, 
protecting from external or internal dangers [22]. Noise or sharp light can in this 
context be viewed as an external danger, whereas hypercapnia and hypoxia has been 
proposed as an internal danger. 
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1.3.3 Sleep architecture 
In adults, a nightly sleep pattern typically starts with NREM in increasing depth of 
sleep before the first episode of REM occurs after 80-100 minutes. Thereafter, 
NREM sleep and REM sleep cycle with a period of approximately 90 minutes [23]; 
REM-sleep constituting approximately 20 % of the total sleep time (TST). With 
increasing age, TST and the TST-percentage of N3 and REM-sleep decreases, 
whereas N1 and N2 TST-percentage and time awake after sleep onset (N0) increases 
[24]. 
 
1.4 Breathing in normal human sleep 
Breathing is primarily regulated by the paCO2; an increase of only 0.13 kPa (1 
mmHg) in paCO2 will increase the ventilation with approximately 2.5 to 3 L/min [25]. 
In sleep, the respiratory system seems to be challenged by a significant reduction in 
minute ventilation and worsening of blood gases [26]. In support of the internal 
defense hypothesis regarding arousals, some studies have shown a paCO2 arousal 
threshold increasing with depth of sleep, with lower threshold values of paCO2 in 
hypoxic compared to hyperoxic conditions [27,28].  
As major functions of respiration during NREM sleep differ from REM sleep, these 
two states are viewed separately, and when considering breathing during NREM 
sleep, the unsteady, light sleep (N1 and part of N2) is separated from the steady, deep 
sleep (stable breathing N2 and N3).  
1.4.1 Drowsiness or unsteady NREM sleep 
At sleep onset, the level of vigilance oscillates for 10 to 20 minutes between arousal, 
N1 and N2 sleep and breathing is unstable, with regular fluctuations of increase and 
decrease in the breathing amplitude [29,30]. This may in turn result in alternating 
hyperventilation and hypoventilation, including apneas of 10-40 seconds at the nadir 
of the oscillations [31,29]. As ventilation is regulated by negative feedback, primarily 
by the paCO2, this breathing instability can be explained by a higher paCO2 set point 
during sleep compared to wakefulness, and by a delay between blood gas changes 
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and chemoreceptor response. Thus, at sleep onset, ventilation is up-regulated or 
down-regulated according to the different set-points [29].  
1.4.2 Stable NREM sleep 
Stable sleep is established only when the ventilation and sleep stage fluctuations 
reach a stable state. Sleep will then typically progress through stable state N2 to deep 
sleep N3. During NREM sleep the ventilation decreases approximately 15% from 
wakefulness, resulting in a paO2 decrease between 0.5 and 1.3 kPa [26], whereas the 
paCO2 increases up to 0.9 kPa above supine awake values [32-34]. These changes 
occur despite a 10% to 20% reduced O2 uptake and CO2 production [29]. Rib cage 
muscular breathing activity is increased in NREM sleep compared to abdominal 
(diaphragm) muscle activity, the total airway resistance increases more than twofold 
and the geniohyoid muscle tone is significantly reduced, all factors contributing to the 
decrease in minute ventilation in stable NREM sleep [35-37]. 
1.4.3 REM sleep 
Breathing during REM sleep is irregular both in frequency and tidal volume, quite 
different from the regular periodic breathing at sleep onset [30]. The breathing 
irregularities are linked to bursts of rapid eye movements, giving name to this 
particular sleep stage. In contrast to NREM sleep, rib cage muscle activity in REM 
sleep is depressed, leaving most of the breathing pump work to the diaphragm. Very 
few studies of REM sleep arterial blood gases in normal subjects have been 
performed. However, the average ventilation, tidal volume and respiratory frequency 
during REM sleep seem to differ little from NREM sleep, there is a lack of reliable 
information on PaCO2 whereas the hypoxemia seen in NREM is unchanged or 
slightly worse in REM sleep [29]. 
 
1.5 Breathing at sleep in COPD 
Polysomnography from COPD subjects has shown poor sleep quality in terms of 
reduced total sleep time, disturbed sleep architecture, and highly frequent arousals 
[38-41]. Compared to normals, sleeping COPD subjects become significantly more 
 21 
hypoxemic than when awake – even more hypoxemic than during exercise at daytime 
[42]. The pO2 is progressively reduced with depth of sleep, with the lowest levels 
during REM sleep, at which oxygen saturation can be extremely low, especially in 
those with low daytime paO2 [43,44]. This hypoxemia is clinically significant as it 
affects the hematologic and cardiovascular system [45-47], and may even contribute 
to nocturnal death [48]. Whether nocturnal hypoxemia affects the quality of sleep in 
terms of sleep fragmentation is unclear, as sleep hypoxia in one study did not increase 
the frequency of arousals [49]. 
1.5.1 Sleep hypoventilation in COPD 
In normal sleep, changes in lung mechanics, muscle contractility and central 
respiratory control lead to hypoventilation, resulting in a moderate increase in paCO2. 
The same mechanisms apply in COPD sleep. However, in these patients the 
hypoventilation seems to be more pronounced, especially in REM sleep, when the 
desaturation during bursts of rapid eye movement is accompanied by hypoventilation 
rather than by apneas [50]. This can partly be explained by the rapid, shallow REM-
sleep breathing which reduces the alveolar ventilation; already compromised by an 
increased physiological dead space typically found in advanced COPD. 
Hypoventilation in COPD is also a consequence of chronic hyperinflation with a 
more or less flattened diaphragm. Thus, the respiratory pump is more dependent on 
the accessory respiratory muscles, in which central control is depressed during REM 
sleep. Finally, hypoventilation increases the brains' extracellular level of bicarbonate, 
blunting the central hypercapnic drive to breathe [51].   
Sleep hypoventilation (SH) has previously been defined as an increase in paCO2 ≥ 1.3 
kPa (10 mmHg) from the awake, supine value. O´Donoghue et al studied 54 stable 
COPD subjects with daytime chronic hypercapnic respiratory failure (CHRF) using 
LTOT, utilizing PSG with ptcCO2, and found that 43% of the patients spent ≥ 20% of 
sleep time with ptcCO2 > 1.3 kPa above waking baseline [52]. Tarrega et al measured 
paCO2 at night (3 a.m.), in the morning (7 a.m.), and at daytime in 80 hypercapnic 
COPD subjects on LTOT , and found 21% of the night or morning samples of PaCO2 
≥ 1.3 kPa above daytime PaCO2  [53]. Thus, SH seem to be highly prevalent in 
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subjects with severe COPD with CHRF on LTOT. However, it is unclear if SH is 
associated to daytime hypercapnia per se, as to our knowledge; no studies prior to 
ours are performed assessing SH in normocapnic or non-LTOT-using COPD 
subjects. Neither has the increase in ptcCO2 (ΔptcCO2) according to sleep stages 
previously been described in detail, hypothesizing greater between stage differences 
in subjects with versus without SH. 
According to the recent revision of the PSG scoring rules from the American 
Academy of Sleep Medicine (AASM), SH is scored when the PaCO2 (or surrogate) > 
55 mm Hg (7.3 kPa) for ≥ 10 minutes or if there is an increase in the paCO2 (or 
surrogate) ≥ 10 mm Hg ( [1.3 kPa] in comparison to an awake supine value) to a 
value exceeding 50 mm Hg (6.7 kPa) for ≥ 10 minutes [54]. 
1.5.2 Overlap syndrome (COPD and obstructive sleep apnea)  
Obstructive sleep apnea (OSA) is diagnosed if the frequency of apneas/hypopneas per 
hour (AHI) ≥ 15, or AHI ≥ 5 with daytime sleepiness, loud snoring, witnessed 
breathing interruptions or awakenings due to gasping or choking [55]. Prevalence of 
OSA in subjects with COPD seems to be no greater than the prevalence of OSA alone 
[56]. However, patients with both COPD and OSA (Overlap syndrome) face an 
increased risk of death and hospitalization because of COPD exacerbation [57]. One 
retrospective study from a sleep center indicated that Overlap patients have more 
severe daytime hypercapnia compared to subjects with COPD or OSA alone [58], but 
to our knowledge, this has not been confirmed by prospective studies. Nor has 
comparisons been made of ΔptcCO2 during sleep in subjects with Overlap versus 
COPD only. 
1.5.3 Treatment of chronic respiratory failure in COPD 
Long term oxygen therapy (LTOT) in COPD patients with daytime hypoxemia 
increases survival and improves quality of life [59-61]. However, the efficacy of 
exclusively nocturnal oxygen supplementation in subjects with episodic sleep 
desaturations has to our knowledge not been evaluated in prospective studies [62]. 
LTOT implies continuous use of supplementary oxygen, including during sleep, a 
treatment which is known to increase the paCO2 in some COPD patients. This 
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hypercapnia can be overcome by simultaneous treatment with nocturnal oxygen and 
non invasive ventilation (NIV) [63]. The beneficial effects of NIV on gas exchange in 
COPD patients was described as early as in 1951 [64], however the search for 
etiology, predictors and effective treatment of CHRF in these patients is still going 
on. The idea of resting the respiratory muscles fatigued by the chronic hyperinflation 
in severe COPD led to a series of studies, first with negative pressure, later with 
positive pressure ventilation. The negative pressures were poorly tolerated, and the 
study results were contradictory regarding improvement of respiratory muscle 
function or daytime paCO2 [65]. Studies utilizing positive pressure ventilation were 
more promising, although three large, randomized trials in 2000, 2002 and 2014 
failed to show improved survival in COPD patients using NIV and LTOT compared 
to LTOT alone [66,67], and in hypercapnic COPD-patients initially treated with NIV 
because of acute respiratory failure [68]. On the other hand, in 2009 McEvoy et al 
found NIV to improve sleep quality and paCO2 and marginally improving survival 
[69], whereas Köhnlein et al recently found significantly improved survival after 12 
months of NIV [70]. Thus, at present, whether NIV should be used in COPD with 
CHRF is a matter of controversy. However, in Overlap patients, continuous positive 
airway pressure (CPAP) treatment has been shown to improve survival and decrease 
hospitalizations [57]. 
 
1.6 Effect of alcohol in COPD and in normal subjects 
Alcohol is known to be both a cause of lung disease and a therapeutic agent. Heavy 
consumption increases the risk of developing COPD [71,72], whereas mild intake is 
associated with higher forced expiratory volume first second (FEV1), less COPD 
symptoms and reduced mortality [73,74]. Since ancient Egypt, alcohol has been 
known to relive chest tightness [75], and intravenous ethanol has been shown to 
relieve bronchial obstruction in subjects with atopic asthma, with roughly 40% of the 
effect of salbutamol [76]. In insomniacs, a moderate dose of alcohol improves sleep 
maintenance [77]. In normal, awake individuals, an occasional, moderate dose of 
alcohol depresses the hypercapnic and hypoxic drive to breathe  [78], and during 
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alcohol influenced sleep, the inspiratory airway resistance is increased and the 
hypercapnic respiratory drive tends to decrease [79,4]. Alcohol also alters the sleep 
architecture resulting in increased N3 and less REM sleep [80], and increased 
frequency of arousals, oxygen desaturations and apneas [81,82]. As many COPD 
patients are hypoxic and hypercapnic when awake, concern can thus be raised 
regarding the risk of further blood gas deterioration in alcohol influenced sleep. 
Indeed, a study of  20 COPD subjects (19 men), showed that alcohol increased the 
number and duration of sleep apneas as well as TST [83], and in another study of five 
individuals with severe COPD (four men), alcohol reduced the TST, REM % of TST 
and the mean oxygen saturation measured by pulse oximetry (SpO2) [84]. However, 
to our knowledge, no previous sleep-studies have been published on alcohol induced 
blood gas changes including ΔptcCO2 and their relation to sleep architecture and 
frequency of apneas/hypopneas. Nor have the association between such blood gas 
changes and daytime COPD characteristics been described. 
 
1.7 Effect of hypnotics in COPD and in normal subjects 
Difficulties in initiating or maintaining sleep, or excessive daytime sleepiness, is 
experienced by more than half of the COPD population [85]. Also, sleep related 
complaints are ranked third, after dyspnea and fatigue, in frequency of complaints in 
these patients [86]. Thus, hypnotics are frequently used despite guidelines 
recommending avoiding such drugs if possible [39,16]. In support of these 
recommendations, a recent, longitudinal, cohort study of 2249 patients with severe 
COPD using LTOT indicated that although the use of benzodiazepines was not 
associated with increased hospital admission rates, these drugs were associated with 
increased mortality with a dose – response trend [87]. True causal effects could not 
be stated however, as the study was not prospectively randomized. 
All currently available hypnotics acts at different moieties of the gamma-
aminobutyretic acidA benzodiazepine receptor complex, and have various degree of 
anxiolytic, muscle relaxant, anticonvulsant, amnesic, as well as sleep promoting 
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properties [88]. The drugs are typically grouped as benzodiazepines and non-
benzodiazepines according to their molecular structure; however, binding to the same 
receptor complex they induce sleep by basically the same mechanisms. In healthy 
subjects, benzodiazepines improve sleep quality by reducing the latency to sleep 
onset and increasing the TST [89], whereas sleep architecture is changed by an 
increased N2 percentage of TST and decreased N1, N3 and REM percentage of TST 
[90]. The longer acting benzodiazepines (e.g. flurazepam) seem to have mild 
respiratory depressant properties in healthy subjects [3]. In COPD patients, the 
intermediate acting benzodiazepine temazepam (half-life of between 8 to 15 hours) 
did not change the patients' mean or highest ptcCO2 during sleep in one of the first 
studies measuring nocturnal ptcCO2 to assess the effects of benzodiazepines [91]. The 
short acting, non-benzodiazepine zopiclone appears to have no significant effect on 
desaturations during sleep, or on daytime blood gases [92]. However, the latter study 
from 1990 included only six patients and did not report nocturnal recordings of pCO2. 
Thus, it is of interest to study whether this frequently used hypnotic induces sleep 
hypoventilation in stable COPD patients. 
Eszopiclone, an isomer of zopiclone, has been shown to reduce the number of 
apneas/hypopneas in subjects with OSA [93], whereas a non-significant trend 
towards an increased AHI was found in the small group of COPD patients on long 
term administration of zopiclone mentioned above [92]. The impact of a single dose 
of zopiclone on the frequency of sleep apneas/hypopneas in stable COPD patients is 
to our knowledge not previously described. 
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2 Study aims 
The purpose of this thesis was to assess the sleep induced changes in blood gases in 
stable COPD-subjects, specifically the phenomenon of sleep hypoventilation in 
association to sleep architecture, apneas/hypopneas and daytime COPD-
characteristics, both in spontaneous sleep and in sleep influenced by alcohol or the 
hypnotic zopiclone. The research questions were: 
Paper I:  
1. Is sleep hypoventilation (SH) associated with daytime hypercapnia? 
2. Is the ptcCO2 increase from pre sleep value (ΔptcCO2) between sleep stages 
different in subjects with versus without SH? 
3. Do subjects with Overlap (COPD and OSA) differ from those with COPD 
only, in ΔptcCO2 or in daytime paCO2? 
Paper II: 
1. How is the sleep architecture, blood gases and frequency of apneas/hypopneas 
changed by a moderate dose of alcohol (0.5 mg per kg bodyweight) prior to 
sleep? 
2. Is the alcohol induced changes in blood oxygen saturation or carbon dioxide 
pressure during sleep associated to daytime COPD characteristics? 
Paper III: 
1. To what extent does 5 mg zopiclone induce sleep hypoventilation in stable 
COPD? 
2. What impact does 5 mg zopiclone have on the frequency of sleep 
apneas/hypopneas in stable COPD? 
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3 Material selection and methodological 
considerations 
3.1 Study setting 
This thesis is based on data collected from inpatients at Glittreklinikken pulmonary 
hospital in Hakadal, Norway. Every year, between 600 and 700 patients with chronic 
obstructive pulmonary disease (COPD) are admitted to the hospital from all parts of 
Norway for four weeks of inpatient pulmonary rehabilitation (IPR). Disease severity 
in these patients varies greatly; some are working fulltime whereas others are on the 
waiting list for lung transplantation. At present, 13 doctors specialized in pulmonary 
and internal medicine, as well as occupational diseases and general practice work at 
Glittreklinikken.  
 
3.2 Study population and sampling 
Inclusion of patients to the study started in April 2009, with only two nights of PSG 
per patient (no "first night" for acquaintance, see 3.4.4 Polysomnograpy below). 
During the first month it became evident that the protocol needed revision regarding 
this point, inclusion was stopped and the data from the first two patients were 
excluded. Then, from January 2010 through June 2011, with revised protocol and 
study logistics, the study leader (author) screened the arrival journal including 
spirometry and laboratory reports of all new patients to decide who were eligible for 
the study. Inclusion criteria were a COPD diagnosis according to the GOLD 
guidelines [2] and being able to complete the routine diagnostic procedures at the 
clinic. Exclusion criteria were a prior diagnosis of OSA, COPD exacerbation within 3 
weeks prior, other serious lung comorbidity (ie, cancer, sarcoidosis, restrictive lung 
disease) or diseases affecting thoracic or abdominal movement, unstable angina 
pectoris, uncontrolled hypertension or diabetes mellitus, myocardial infarction within 
last 3 months, cerebral infarction  and addiction to drugs, alcohol, or narcotics.  
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At the end of each week, the list of eligible patients with PaCO2< 6.3kPa 
(normocapnic) were numbered in randomized order. To stratify for gender, a "male" 
or "female" tag was blindly selected from a box; the selected gender with the highest 
number on the list was the first one to be asked to participate. Then the tag was put 
back and a new, blind, gender selection was done, and so on. If a patient declined to 
participate I moved to the next one on the list with the same gender. The same 
procedure was applied if information about alcohol problems or drug abuse not given 
in the arrival journal became evident during the inclusion interview. However, one 
specific case was excluded, recorded as missing due to information about regular 
benzodiazephine use which came up after the person had been included and the first 
PGS had been recorded.  
According to the calculations of sample size in the study protocol (see 3.5.4 
Statistics), we intended to include 60 normocapnic subjects and 60 subjects with 
PaCO2 ≥ 6.3kPa (CHRF). However, after the initial study start in April 2009 it 
became evident that the hypercapnic subjects were indeed few. Thus, to include as 
many CHRF patients as possible, these were oversampled by asking all who were 
eligible to participate in the study, not stratifying this group for gender, and in priority 
of the normocapnic subjects. Despite this, I was not able to include the intended 
number of CHRF subjects in the time available for inclusion. 
After informed and written consent to participate, the subjects were randomized to 
receive alcohol, zopiclone or supplementary oxygen prior to one of the nights of PSG 
by selecting a tag with an "A", "Z" or "O" respectively from another box. The box 
contained 10 tags of each letter, when empty; all 30 tags were put back. The order of 
interventional or spontaneous sleep was finally randomized by blind selection of "I" 
or "S" tags from yet another box. 
We had the equipment and personnel capacity to include a maximum of three patients 
per week. As shown in figure 1, 166 patients were eligible and invited during the 
study period of 18 months. Among the 26 declining to participate, three patients did 
not want to stop taking zopiclone for the time required and another two did not want 
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to take pills or alcohol (supplementary material to Paper I has a detailed description 
of the other reasons for not participating). 66 PSG's were lost prior to analysis of 
control (spontaneous) sleep, and another 11 PSG's were excluded prior to analysis of 
interventional sleep compared to control sleep. 
Figure 1 Study inclusion  
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3.3 Study design 
Table 1 Design and methods for the three included papers 
Paper Design Method N Comparison 
I Observational Independent samples of 
PSG with ptcCO2 
100 CHRF yes/no 
SH yes/no 
II Randomized, not 
blinded cross-over 
Paired samples of PSG 
with ptcCO2 
26/26 Each subject its 
own control 
III Randomized, not 
blinded cross-over 
Paired samples of PSG 
with ptcCO2 
31/31 Each subject its 
own control 
 
In paper I, the degree of daytime hypercapnia and sleep hypoventilation were 
analyzed in 100 stable COPD-patients. Arterial blood gases were sampled at daytime 
prior to the PSG, and according to their paCO2-value the patients were divided in two 
groups; with or without CHRF. Following PSG and ptcCO2 analysis the patients were 
then re-divided in another two groups; with or without SH. The distribution of 
demographics, lung function and other clinical and laboratory data collected at 
daytime, as well as sleep parameters including TST, awakenings, sleep stage 
distribution, apneas/hypopneas, arousals, increase in ptcCO2 and minimum SpO2 were 
then compared according to whether or not the patient had CHRF or SH. 
In paper II, twenty-six of the patients described in paper I served as their own control 
in evaluating the effect of 0.5 mg alcohol per kg bodyweight on sleep architecture 
and nocturnal ventilation. Alcohol as 96% ethanol was diluted in approximately 200 
ml of orange juice and ingested as fast as possible after the patient had gone to bed. 
To ensure alcohol was taken, breath analysis by alcometer was performed 
immediately before the nurse turned off the light.  
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The same design was applied in paper III, analyzing the effect of 5 mg zopiclone 
taken orally as a pill approximately 30 minutes prior to sleep by another 31 of the 100 
patients in paper I. 
No patient received more than one intervention. 
 
3.4 Measurements 
3.4.1 Lung function testing 
All pulmonary function tests were performed by experienced laboratory personnel 
according to standardized criteria [94-96]. Reference values were based on data from 
the European Community for Steel and Coal [97].  Testing of post bronchodilator 
spirometry (FVC, FEV1), static lung volumes (TLC, RV) and diffusion capacity of 
the lungs (DLCO) were performed on MasterScreen Pneumo, Jaeger-Toennies, 
Hoechberg, Germany. At Glittreklinikken, volume calibration using a 3 liters syringe 
is performed daily, as well as ambient pressure adjustments, gas calibrations and 
body box (pletysmography) volume settings. Biologic quality controls are run 
weekly.  
3.4.2  Measurement of dyspnea, prognostic considerations 
The five point Modified Medical Research Council questionnaire (MMRC) [98]  
originates from England but is widely used in clinical as well as scientific settings 
[98]. To our knowledge, a validated Norwegian version was not available. Hence, 
prior to study start a translated draft in Norwegian was translated back to English by 
teacher, author and translator Richard Peel, a native Englishman with university 
education from Oxford, Bristol, Oslo and Bergen and with more than 30 years 
occupational experience in Norway. Mr. Peel did not initially know the original 
English version. After the back-translation he participated in a discussion with a 
group of physicians at Glittreklinikken (specialists in pulmonary, occupational and 
general medicine) regarding a few words of discrepancy between the original and his 
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back-translated English text, and a consensus was agreed on the final Norwegian 
version. As the translation was not tested by cognitive debriefing or other methods of 
patient interviews it can be argued that it is not fully validated. However, by using a 
questionnaire with the original English text above the Norwegian translation of the 
five paragraphs I consider the scoring to be sufficiently accurate for our purpose (see 
appendix 7.1). 
The BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) 
index is a prognostic indicator in COPD [99]. BMI was calculated from the patients' 
weight and height, airflow obstruction as FEV1 measured by spirometry, dyspnea 
graded by the MMRC and the exercise capacity indicated by the 6 minute walking 
distance (6MWD). MMRC score and BODE index is reported in all three papers 
[100]. 
3.4.3 Arterial blood gases 
Arterial blood gas samples reported in all three papers were obtained at 
approximately 2 pm prior to the PSG nights. After at least 5 minutes of seated rest, 
about 3 ml of blood was drawn by single puncture of the patients' radial artery.  Pre-
heparinized syringes were used1, air bubbles immediately removed and the samples 
analyzed on ABL 720Flex2 within 10 minutes. No complications were observed 
during or after this procedure. The blood gas analyzer was calibrated and quality 
controlled several times daily according to the manufacturers' recommendations, 
precision and accuracy was additionally controlled by an external laboratory quality 
system3. All blood gas analyses were performed by experienced personnel. 
                                            
1PICO 50, Radiometer, Copenhagen, Denmark 
2 Radiometer, Copenhagen, Denmark 
3 Labquality Oy, Helsinki, Finland 
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3.4.4 Polysomnography 
To record electrical activity in the brain, EEG electrodes with contact gel were placed 
on the scalp at positions A1, A2, C3, C4, O1, O2 and GND (described in detail on 
page 23 in the AASM Manual for the Scoring of Sleep and Associated Events [19]). 
Also according to the AASM recommendations, ocular muscle activity was recorded 
by one EOG electrode lateral to each eye, and muscle activity by EMG electrodes one 
on each side of the chin and one on each leg. Heart muscle activity was recorded by 
two ECG-electrodes, one on each of the clavicles. All electrodes were kept in place 
by tape and a head net bundled the thin wires, emerging at the vertex (figure 7, 
section 5.1.3 Polysomnography). Nasal flow was detected by a pressure sensor 
through a plastic cannula placed in the patients' nostrils. Thoracic and abdominal 
movements were recorded by stretch sensitive belts, and patient position by a sensor 
fixed to the thoracic belt as shown in figure 7. A probe for pulse oximetry4 (section 
3.4.6) was taped to one finger tip, and the TOSCA 5005 probe (section 3.4.5) for 
recording the ptcCO2 and another pulse oximetry signal was fixed to the forehead. All 
electrodes, probes, sensor and belts were fixed between 5 and 7 pm and connected 
through the EMBLA A106 system to an online recording computer with Somnologica 
Studio Version 3.3 software7. A bedside trolley carried the computer and its screen, 
the EMBLA A10 system, the TOSCA 500, and an extension power cable long 
enough for the patient to reach the toilet. Sufficient signal quality was checked in the 
computer program, and then the patient was disconnected from all devices, carrying 
the cables in a small bag at the waist. Although one patient reported scaring a moose 
on a walking trail outside the clinic with his odd headgear, most of the study subjects 
stayed at their room until re-connecting to the computer at bedtime. After helping the 
patient to bed and connecting the cables and the TOSCA 500 sensor, the night nurse 
                                            
4 Nonin Medical Inc., USA 
5 Radiometer, Basel, Switzerland 
6 Medcare Flaga, Reykjavik, Iceland 
7 Medcare, Flaga 
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gave alcohol, zopiclone or oxygen when appropriate, and started the recording. After 
approximately 30 minutes she returned to the patients' room, controlled the quality of 
the PSG recording on the screen, checked whether alcohol was actually taken using 
an alcometer8, noted the estimated blood alcohol content, the ptcCO2 reading on the 
TOSCA 500 and finally the time as she turned off the lights. If the patient was in 
need of going to the toilet during the night, the trolley was brought along; 
alternatively a bedside commode was used. The night nurse silently looked in to the 
patient's room several times during the PSG recording and was instructed to wake the 
patient if the ptcCO2 had increased more than 3 kPa from the value at lights off. 
When the patient woke in the morning, the nurse was called. She noted the time and 
any events during the night (trouble with falling asleep, periods awake, toilet visits, 
technical problems etc), stopped the recording and removed electrodes, belts sensor 
and probes. The recording was quality assessed before it was sent it to the 
polysomnographist for sleep scoring. 
3.4.5  Transcutaneous pressure of carbon dioxide (ptcCO2) 
The method implied fixing a probe in a drop of contact gel to the skin on the patients' 
forehead as shown in figure 7, section 5.1.3. The skin was heated to 42 degrees 
Celsius by the probe in order to maximize the arterial flow in the capillary bed below 
the sensor.  According to the manufacturer this temperature is tolerated for up to 12 
hours without causing tissue damage [100]. The carbon dioxide pressure (pCO2) 
sensor of the TOSCA 500 consists of a Stow-Severinghaus type electrode in which 
the pCO2 is measured by determining the pH of an electrolyte solution; a change in 
pH being proportional to the logarithm of the pCO2 change. Generally, there is a high 
correlation between paCO2 and ptcCO2. However, when the skin is heated the ptcCO2 
is elevated approximately 4.5% per degrees Celsius and the living epidermal cells 
produce their own CO2, contributing to the capillary pCO2 with approximately 0.65 
                                            
8 Lion Alcometer 500, Lion Laboratories Ltd., Vale of Glamorgan, UK. 
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kPa [101]. The signal from the sensor is calibrated within the TOSCA 500, output 
value adjusted to compensate for these effects. 
In addition to this calibration there were several other aspects to be considered 
regarding the use of ptcCO2 in this study; the following briefly described pilot studies 
are not previously published.  
First, to investigate whether ptcCO2 changes could substitute for paCO2 changes, 
clinical data were obtained from 18 (14 male) stable COPD subjects prior to the main 
study (supplementary material, Paper I). All had an indwelling arterial catheter and 
the TOSCA probe fixed to an earlobe according to the manufacturers' 
recommendations. Arterial samples were drawn from the catheter every 20th minute, 
simultaneously recording the ptcCO2 displayed on the TOSCA. The arterial samples 
were analyzed within five minutes; 9 to 18 pairs of paCO2 ptcCO2 data being obtained 
from each patient. The mean of the SD's for each patients' set of data pairs was 0.19 
kPa (ranging from 0.13 kPa to 0.30 kPa). As we intended to record the pCO2 changes 
in sleeping COPD patients, this variance of the ptcCO2 - paCO2 difference for each 
individual was the matter of interest, more than the difference itself. Thus, with near 
95% probability the ptcCO2 value recorded would be 0.38 kPa below or 0.38 kPa 
above the paCO2 + (ptcCO2 - paCO2); a total variance range of 0.76 kPa. We found 
this variance acceptable to regard ptcCO2 changes as a surrogate for changes in paCO2 
during sleep in this patient group.  
Second, as we used two capnographs during the study we wanted to investigate 
whether the TOSCA 500 appliances display identical values when measuring ptcCO2 
simultaneously on the same subject. Clinical data was obtained from another 8 COPD 
patients in two different situations. The two ptcCO2 probes were fixed one on each 
side of the sagittal line at the forehead, center of probes 32 mm apart. After 
stabilization of approximately 30 minutes the ptcCO2 differences were recorded once 
every 30th second for 10 minutes (21 readings). Then, to reveal any significant, skin 
thickness, or local vascular differences, the probes switched place and new stable 
readings were obtained as described above. Data showed TOSCA #2 displaying 
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significantly higher ptcCO2 values compared to TOSCA #1 regardless of its probe 
being fixed to the left versus right side of the forehead, the mean (SD) difference 
between the readings being 0.30 (0.24) kPa and 0.24 (0.21) kPa respectively (p<0.05 
in both situations). We concluded that differences observed between paCO2 and 
ptcCO2 partly may depend on the transcutaneous appliance used, and with the 
importance of using the same capnograph for all recordings on the same patient.  
Third, a delay time from an alveolar change in pCO2 until the first response in ptcCO2 
is expected. As described in the supplementary material to Paper 1 (and in poster, 
Appendix 7.2), nine COPD patients (six male) were studied. The supine study subject 
was breathing through a tight fitting mask with an inlet valve selecting either room air 
or a gas mixture of 4% CO2 in air from a bag. Data were collected during three 
phases, each lasting 200 sec: 1) stable phase breathing room air, 2) increasing phase 
breathing 4% CO  in air, and 3) decreasing phase after switching back to breathing 
room air. ptcCO2 was recorded every 5th second for two minutes, then every 10th 
second in each phase. Arterial samples were drawn from an indwelling arterial 
catheter three times during phase 1), every 5th second the first 30 sec of phase 2) and 
3), then every 30th sec for a total of 150 sec. We defined first response time (FRT) as 
the time from an alveolar pCO2 change (start of phase 2) until ptcCO2 had changed 
more than two SD's from the mean value of phase 1).  Results showed a mean (SD) 
FRT in increasing phase of 54 (18) sec, and in decreasing phase 57 (15) sec. For 
paCO2 the FRT was 13 (6) sec and 12 (3) sec respectively. Thus, the ptcCO2 data 
recorded in the PSG were left shifted two sleep epochs (60 sec) prior to data analysis.  
Finally, in some of the first recordings we found ptcCO2 sharply increasing < 20 kPa 
with simultaneously slightly increased SpO2-values. This was suspected to be an 
artifact resulting from the ptcCO2 probe being compressed between the ear and the 
pillow. Thus, due to this observation we fixed the probe to the forehead instead of the 
earlobe for the rest of the study. Nevertheless, a few recordings with the probe on the 
2
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forehead had to be excluded as well, due to a similar artifact when the probe was 
compressed between the patients' forehead and arm (figure 2). 
Figure 2 Compression of TOSCA9 probe between arm and forehead 
 
Notes to figure 2: Transcutaneous pressure of carbon dioxide (ptcCO2 [kPa]) measured by TOSCA on the y-axis, time in 
minutes on the x-axis. The TOSCA probe was applied to author' forehead in supine position. After a stabilizing period of 
approximately 2 minutes (11:24 – 11:26), the probe was compressed by the dorsal side of left underarm for about 14 
minutes (11:26 – 11:40). An arterial blood gas sample was obtained from the right a.radialis before compression was 
terminated at 11:40; measured values inserted in text box. As shown, paCO2 was 5.0 kPa whereas ptcCO2 was measured to 
23.6 kPa. 
 
                                            
9 Radiometer, Basel, Switzerland 
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3.4.6 Pulse oximetry (SpO2) 
Pulse oximetry is commonly used in clinical and scientific settings [102,103]. The 
arterial oxygen saturation is computed by comparing the transmission of two 
wavelengths of red light (absorbed by deoxyhemoglobin) and infrared light (absorbed 
by oxyhemoglobin) either through e.g. a finger tip or as a reflection from a white 
surface. Two light emitting diodes are switched on and off several hundred times per 
second; thus light absorption by oxyhemoglobin and deoxyhemoglobin is recorded 
during pulsatile and nonpulsatile flow. Microprocessors compute the arterial oxygen 
saturation, updating the average of the last 3-6 seconds every 0.5-1 second [104]. It is 
not possible to calibrate a pulse oximeter, but they have an accuracy of approximately 
1-2 % compared to the "gold standard" SaO2 [105]. In this study two different SpO2 
probes were simultaneously used; one taped to a finger tip, the other integrated in the 
TOSCA 500 sensor fixed to an earlobe or at the forehead. The latter recorded a signal 
reflected from the white plastic fixing clip at the ear lobe or the white skull bone on 
the forehead. The SpO2 signal from the finger tip was processed in the EMBLA A10, 
trace recorded in the PSG whereas the computed SpO2 signal from the TOSCA 500 
was recorded as a separate trace in the same PSG. 
 
3.5 Analyses 
3.5.1 Sleep scoring 
Sleep was scored according to the 2007 AASM manual based on traces of EEG, EOG 
and EMG, thoracic and abdominal respiratory movements, nasal airflow and arterial 
oxygen saturation, commencing at lights-off-time in the evening (intention to sleep) 
and ending at rise time in the morning. Each epoch of 30 seconds was scored as stage 
N1, N2, N3, REM-sleep or N0 (awake after initial sleep onset). According to the 
AASM recommendations (criterion A), a hypopnea was scored when nasal pressure 
dropped ≥ 30% for ≥10 seconds with ≥ 4% desaturation drop from baseline, with ≥ 
90 % of the event's duration meeting the amplitude reduction criteria for hypopnea  
[54]. Overlap (COPD + OSA) was diagnosed if the frequency of apneas/hypopneas 
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per hour of sleep (AHI) ≥ 15 as we did not have systematically recorded data on 
daytime sleepiness, loud snoring, witnessed breathing interruptions or awakenings 
due to gasping or choking [55]. Also as defined by the AASM, SH was scored when a 
sum of ≥ 20 epochs (10 minutes) of the total sleep time showed an increase in the 
mean ptcCO2 ≥ 1.33 kPa above the pre-sleep ptcCO2 and to a level > 6,7 kPa [19]. 
Results according to the other definition of SH given by the AASM, as a ptcCO2 > 7.3 
kPa for ≥ 10 minutes of sleep, was reported only in Paper III. Like SpO2, the ptcCO2 
was recorded as a continuous trace in the PSG, however, as apneas or hypopneas 
resulting in alveolar changes in pCO2 will be apparent as changes in ptcCO2 after 
approximately 1 minute (section 3.4.5 above), the ptcCO2 recording was time 
corrected accordingly prior to calculations of whether SH was present or not. 
Sleep scoring was done by two independent, experienced polysomnographists, a 
random selection of 10 PSG's were scored by yet another two experienced sleep 
scorers and the results from the  initial scorer with the best match to the two latter 
were chosen for analysis.  
3.5.2 ptcCO2 analyses 
The TOSCA 500 recorded the ptcCO2 value 10 times per second; these data were 
exported from the Somnologica to the Statistical Package for the Social Sciences 
(SPSS) software for further calculations. Pre-sleep ptcCO2 was defined and calculated 
as the mean value of the first 3 minutes of the last 6 minutes prior to sleep onset. As 
sleep is scored in epochs of 30 seconds, the mean ptcCO2 of each epoch was 
calculated and the maximum value was recorded. These values were time corrected 
two sleep epochs backwards to synchronize with the other PSG events of that 
particular epoch (as described in section 3.4.5). This enabled calculation of the mean 
ptcCO2 of each sleep stage as the mean of all epoch's mean ptcCO2 of that particular 
sleep stage, and calculation of the mean increase of the ptcCO2 (meanΔptcCO2) as this 
sleep stage's mean ptcCO2 minus pre-sleep ptcCO2. The NREM mean ΔptcCO2 was 
calculated as the mean of all NREM epoch's mean ptcCO2 minus pre-sleep ptcCO2, 
whereas the total sleep mean ΔptcCO2 was calculated as follows: (NREM 
meanΔptcCO2 *NREM sleep time/total sleep time) + (REM meanΔptcCO2 *REM 
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sleep time/total sleep time). Also, the maximum ptcCO2 increase (Max Δ ptcCO2) was 
reported for each sleep stage, for NREM sleep and for total sleep.   
3.5.3 SpO2 analyses 
The data from the two separate, continuous SpO2 traces in Somnologica were 
exported to the SPSS and the average SpO2 from the TOSCA 500 and the EMBLA 
A10 was calculated for each epoch and each sleep stage, for NREM sleep and for 
total sleep. Likewise, the minimum SpO2 was recorded for each epoch, each sleep 
stage, etc. As we experienced several technical flaws with the finger tip sensor 
(loosening from finger and breakage in the electronic circuitry), the SpO2 signal from 
the TOSCA 500 was chosen for the mean and minimum SpO2 calculations reported in 
all three papers. However, as the finger tip sensor provides the default signal in the 
EMBLA A10, this trace was routinely used for sleep scoring provided it was of 
acceptable quality. 
3.5.4 Statistics 
The main working hypothesis prior to this study was that patients with CHRF had 
greater ΔptcCO2 increases during sleep than normocapnic subjects. Thus, to calculate 
sample size prior to patient inclusion, we analyzed nocturnal ptcCO2 data from 20 
COPD-patients (seven with CHRF) at Glittreklinikken (clinical data, not published). 
Measurements were done by TINA10, reporting ptcCO2 every 5th minute. As PSG was 
not recorded, printed reports from TINA were manually screened to find a stable 
ptcCO2-value 15-30 minutes prior to expected time of sleep onset (pre sleep ptcCO2), 
and the maximal ptcCO2-value during the night. The maximal ptcCO2 increase 
(maxΔPtcCO2) was calculated for each patient by subtracting the pre sleep ptcCO2 
from the maximal ptcCO2. For the whole group the standard deviation (SD) of these 
maxΔptcCO2-values was 0.95 kPa. A clinically significant difference in the mean 
values of maxΔptcCO2 between the groups with CHRF versus the normocapnic 
subjects was considered to be at least 0.5 kPa. Thus, standardized difference was 
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calculated to 0.53 (0.5 kPa/0.97 kPa), and with power of 85% and a 2-sided 
significance level of 0.05, necessary sample size was calculated to 120 subjects in 
total (i.e. 60 normocapnic and 60 with CHRF) [106]. 
To get an impression of the statistical power prior to analysis of data from the 
interventional studies (alcohol and zopiclone), results from spontaneous sleep were 
used to calculate sample size. The SD of the mean increase in ptcCO2 during 
spontaneous sleep was 0.32 kPa; we assumed this to be unchanged during alcohol and 
zopiclone sleep. A minimal detectable difference of 0.25 kPa was considered 
clinically significant for the interventional studies. Thus, with 80% power and a two-
sided significance level of 0.05, calculations showed that N=28 subjects were needed 
for each study. 
Concordance between the sleep scorers were measured by Cohen's kappa. Prior to 
statistical analysis, all data were assessed for normality and homogeneity of variance, 
the normally distributed data presented as mean (SD) or median (interquartile range) 
whereas data with skewed distribution being presented as median (interquartile 
range). Differences in continuous variables between groups were analyzed with 
Student's one sample t, Mann-Whitney U or Kruskal-Wallis tests as appropriate, 
differences in categorical variables by Pearson chi-square or Fisher's exact test. 
Differences in continuous variables within groups (paired data) were analyzed by 
Student's two samples t-test (parametric data) or Wilcoxon signed rank test (non-
parametric data). Paired proportions were assessed by McNemar chi square test (p-
values without Yates' correction). Correlations between variables were assessed by 
Pearson's r. 
In Paper I and II, hierarchial multiple regressions were performed. In Paper I to assess 
whether the maximal CO2 increase during sleep independently predicts daytime 
arterial pCO2 when controlling for COPD severity and use of supplementary oxygen, 
and in paper II to determine whether the decrease in oxygen saturation in alcohol 
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influenced sleep can be explained by daytime COPD characteristics. Calculations 
were performed using IBM SPSS Statistics version 19 and 2011. 
 
3.6 Ethics 
3.6.1 General aspects 
Results from most of the standard procedures and tests for all inpatients at 
Glittreklinikken (eg spirometry, body pletysmography, venous and arterial blood 
sampling, ECG etc) were utilized in the study. In addition the study patients were 
asked to fill in questionnaires (MMRC, CAT, etc), we drew two extra arterial samples 
for blood gas analysis and they went through three nights of PSG with ptcCO2. The 
included patients had to refrain from hypnotics, other respiratory depressing drugs 
and alcohol other than study medication or study alcohol from 48 hours prior to first 
PSG and until they had finished all study tests. In addition, we estimated expiratory 
flow limitation by negative expiratory pressure and by impulse oscillometry and we 
recorded 24 hour ECG (results published elsewhere but not reported in this thesis).  
Puncture of the radial artery can lead to infection or inflammation; in worst case 
destruction of the artery with compromised circulation of the hand. Likewise, venous 
puncture can result in infection or inflammation. However, when following standard 
hospital procedures the risk of such complications is minimal. A transient pain due to 
subcutaneous bleeding from the artery is not unusual but is considered negligible by 
most patients. 
For the recording of PSG, electrodes are mounted at the scalp, laterally to the eyes, on 
the cheeks, chest and legs; belts are fixed around the abdomen and thorax, an air flow 
sensor under the nose, a SpO2-probe taped to one finger and finally a probe for ptcCO2 
and another SpO2 measurement at the forehead. This mounting procedure takes up to 
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an hour; the patient can not shower with the equipment and have to bring the trolley 
with computer and instruments along to the toilet if necessary. This can obviously 
result in some discomfort and reduced sleep quality. However, we followed standard 
procedures for PSG recording according to the AASM to minimize the discomfort, 
and as previous studies have shown only the first night to differ from the next ones 
regarding sleep architecture [107,108] we did not consider this distortion to be a 
significant problem for the participants. 
Patients were anonymized by giving each a unique number and all study results were 
identified by this number. The list connecting the patients' name to this number was 
kept in a password secured file not open to anyone but the study leader. 
3.6.2 About giving alcohol 
Giving alcohol to a person with a former dependency of alcohol can lead to relapse of 
the problems, and some are teetotalers of other reasons. To avoid inclusion of such 
patients, I read the arrival journal looking for a history of alcohol problems or 
substance abuse prior to invitation to participate in the study. Also, the patient was 
specifically asked about drinking habits and use of potentially addictive drugs during 
the inclusion interview. The amount of alcohol given was calculated to give an 
alcohol concentration of approximately 0.7 parts per thousand 90 minutes after 
drinking, equivalent to a moderate intoxication without being considered overly 
drunk. The same amount of alcohol per kg body weight has previously been used in 
studies of COPD patients [84,109]. As a precaution for CO2 narcosis due to retention 
in alcohol sleep, the ptcCO2 values were checked every other hour by the night nurse, 
with instruction to wake the patient if the ptcCO2 increase exceeded 3 kPa. If they 
were not able to wake the patient the doctor would be called. 
3.6.3 About giving zopiclone 
Patients using zopiclone or other hypnotics were asked to refrain from such 
medication 48 hours prior to first PSG and throughout the study, and they were free 
to withdraw from the study at any time during the week of tests. In fact, three patients 
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rejected to participate of this reason, and another patient was excluded after initial 
inclusion due to use of a benzodiazepine. Zopiclone is known to reduce the 
hypercapnic ventilatory response in awake, healthy individuals [110], and as COPD 
patients often have worse ventilation/perfusion matching in their lungs compared to 
normal subjects, hypoventilation during sleep was expected. However, as this drug is 
regularly used by thousands of COPD patients, and with the precaution to wake the 
patient if the ptcCO2 increased more than 3 kPa, we regarded the risk of harmful CO2 
retention to be low. 
With the precautions taken and considerations as described above, we felt it safe to 
ask the patients to participate in the study, and the protocol was approved by the 
Ethical Committee of Eastern Norway, the Ministry of Health and Social Affairs and 
the Data Protection Authority of Norway. 
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4 Main results 
Our findings with reference to the numbered research questions in section 2 Study 
aims are presented below. 
4.1 Sleep hypoventilation 
1. Is sleep hypoventilation (SH) associated with daytime hypercapnia? 
Patients with daytime hypercapnia (CHRF) as a group had a greater maximal 
CO2 increase from pre sleep value (sleep max ΔptcCO2) and SH was more 
frequently found compared to the normocapnic patients (median (IQR) 1.2 
(0.8) kPa versus 0.8 (0.4) kPa (P=0.003), and 9 subjects versus 6 subjects 
(P=0.001), respectively). However, only one of the 6 normocapnic SH subjects 
used LTOT, and as a group these six subjects had significantly better FEV1 
compared to the group of 9 hypercapnic SH subjects (median (IQR) 1.5 (0.8) 
L versus 0.6 (0.3) L respectively). As sleep hypoventilation by various 
definitions previously has been a frequent finding in severe COPD with CHRF 
and LTOT [52,53], we wanted to investigate whether the sleep max ΔptcCO2 
can independently predict daytime paCO2 when controlling for COPD severity 
(FEV1) and use of supplementary oxygen (LTOT). A hierarchical multiple 
regression model was performed; after entering FEV1 (liters) and LTOT 
(yes/no) at Step 1, 52% of the variance in daytime paCO2 was explained. After 
entry of sleep max ΔptcCO2 (kPa) at Step 2 the total variance explained by the 
model was 56%. Thus, sleep max ΔPtcCO2 explained an additional 4% of the 
variance in daytime PaCO2 after controlling for LTOT and FEV1. Figure 3 
illustrates the association between FEV1, PaCO2, use of LTOT and SH. 
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Figure 3 Forced expiratory volume first second ( FEV1) versus daytime arterial pressure of carbon 
dioxide (PaCO2), markers on sleep hypoventilation (SH) and long term oxygen therapy (LTOT), 
horizontal line indicating hypercapnia (6,3 kPa) 
 
 
 
2. Is the ptcCO2 increase from pre sleep value (ΔptcCO2) between sleep stages 
different in subjects with versus without SH? 
In subjects without SH, we found a pattern of gradual increase in the mean 
ΔptcCO2 according to sleep stages, as indicated in figure 4 below. In the SH 
patients, this pattern was not so evident, as the mean ΔptcCO2 was the same in 
stages N2 and N3. Nevertheless, the difference between NREM and REM 
sleep was twice as high in the SH-group compared to the No-SH group. A 
different pattern is evident when looking at the median of the maximal 
ΔptcCO2 (cluster 3 and 4 in figure 4), as lower values are recorded during N3 
sleep, both in the No-SH and in the SH group. This is in accordance with the 
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more stable breathing pattern typically found in N3 as compared to N1, N2 
and REM sleep (see section 1.4.2). 
  
Figure 4 ΔptcCO2 according to sleep stages 
 Notes to figure 4: Each bar represents the sleep stage median value of the mean, and alternatively the maximal 
ΔptcCO2 in kPa. The first and third clusters represent the 85 patients without sleep hypoventilation (no SH), 
second and fourth clusters represent the 15 patients with sleep hypoventilation (SH). 
 
3. Do subjects with Overlap (COPD and OSA) differ from those with COPD 
only, in ΔptcCO2 or in daytime paCO2? 
Despite exclusion prior to the study of patients with previously diagnosed 
OSA, only 25 of the 100 subjects had less than 5 apneas/hypopneas per hour 
(AHI). As the study was not designed for diagnosing OSA, no record of 
daytime sleepiness or other OSA-symptoms was available; hence AHI ≥ 15 
was chosen to define Overlap, whereas subjects with AHI < 5 were defined as 
COPD only. During sleep, the group of 27 Overlap patients had lower 
minimum REM sleep SpO2 compared to the group of 25 patients with COPD 
only (median (IQR) 78 (19) % versus 87 (8) % respectively). However, no 
differences were found in the mean or maximal ΔptcCO2 or in the frequency of 
SH between the groups, nor did they differ in daytime paCO2. 
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4.2 Alcohol intervention 
1. How is the sleep architecture, blood gases and frequency of apneas/hypopneas 
changed by a moderate dose of alcohol prior to sleep? 
Alcohol sleep was compared to control sleep in 26 subjects (nine males). As a 
group, they spent less time in REM sleep as percentage of TST when 
influenced by alcohol; they also had less awakenings and slightly increased 
mean ΔptcCO2 (mean differences (SD) 3 (7) %, 8 (13) awakenings and 0.10 
(0.25) kPa, respectively). The groups mean SpO2 (SD) was 0.9 (2.1) % lower in 
NREM alcohol sleep, whereas no significant SpO2 changes were found in REM 
sleep or N0 (awake after initial sleep). Neither did alcohol change the groups 
mean frequency of oxygen desaturations per hour (ODI) or the AHI. However, 
as indicated in figure 5, several subgroups showed opposite characteristics; as 
approximately one third of the patients increased their REM % of TST, and 
about one third had lower values of ΔptcCO2 during alcohol influenced sleep. 
Also, in the subgroup of 6 patients with Overlap, we found lower AHI and 
ODI during alcohol sleep, whereas the mean ΔptcCO2 increased and the REM 
% of TST decreased in this group (see table 3 in paper II).  
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Figure 5 Alcohol induced changes in mean ΔptcCO2 versus changes in REM percentage of TST
 
Notes to figure 5: Each subject (N=26) is represented by a colored figure according to group (legend in panel). 
Mean PtcCO2 in group 1 (median (IQR) 0.26 (0.28) kPa) differed significantly from group 3 (-0.20 (0.23) kPa, 
P<0.0005), but not from group 2 (0.11(0.10) kPa, P=0.027). The change in REM percentage of TST was 
significantly different between the groups 1 and 2 (median (IQR) = -4.5 (6.9) % versus 3.9 (8.9) %, P=0.001).  
Abbreviations: Change in mean ΔPtcCO2=difference in the mean increase in transcutaneous carbon dioxide 
pressure between alcohol and control sleep. Change in mean REM % of TST=difference in the mean rapid-eye-
movement-sleep-percent of total sleep time between alcohol and control sleep. 
 
2. Is the alcohol induced changes in blood oxygen saturation or carbon dioxide 
pressure during sleep associated to daytime COPD characteristics? 
In the group of 26 patients, three LTOT-users were outliers in the data 
distribution of the mean SpO2 change. When controlling for LTOT, the 
changes in the mean SpO2 induced by alcohol was correlated to daytime paO2 
and inversely correlated to paCO2 (Pearson's r=0.5 (P=0.009) and r=-0.6 
(P=0.002), respectively). However, this was not the case regarding the alcohol-
sleep changes in the mean ΔPtcCO2, nor did changes in the mean SpO2 or mean 
ΔPtcCO2 during alcohol-sleep correlate to spirometry or demographic data. A 
hierarchical multiple regression model with LTOT, daytime paCO2 and paO2 
explained 49% of the variance in the alcohol induced SpO2 change. 
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4.3 Zopiclone intervention 
1. To what extent does 5 mg zopiclone induce sleep hypoventilation in stable 
COPD? 
Without significantly changing the mean REM-sleep percentage of TST in the 
31 subjects as a group, zopiclone increased the mean ΔPtcCO2 from baseline; 
both in REM sleep, NREM sleep and even in stage N0 (awake after sleep 
onset) with a mean (SD) of 0.25 (0.40) kPa, 0.22 (0.32) kPa and 0.14 (0.27) 
kPa, respectively. The number of patients with SH increased from 6 subjects 
(19%) to 13 subjects (42%). REM sleep minimum oxygen saturation did not 
change significantly from baseline to zopiclone sleep. 
 
2. What impact does 5 mg zopiclone have on the frequency of sleep 
apneas/hypopneas in stable COPD? 
No significant difference was found in the median AHI between baseline and 
zopiclone sleep considering the whole group. However, in the subgroup of 11 
subjects with Overlap (AHI≥15), zopiclone reduced the AHI with a median 
difference (IQR) of -8.5 (7.8), and an inverse correlation was found between 
the baseline AHI and zopiclone-baseline AHI-difference, as shown in figure 6. 
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Figure 6 Baseline apnea/hypopnea index (AHI) correlates inversely with Zopiclone – baseline AHI difference 
 
Notes to figure 6: Each subject (N=31) is represented by a dot. Pearsson correlation r= -0.65 (P<0.0005) 
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5 General discussion 
The results from the study are discussed in detail in the papers I-III. In this general 
discussion, the study limitations and some of the methodological considerations are 
highlighted, as well as the SH phenomenon in relation to CHRF, as observed in 
spontaneous sleep and during sleep influenced by alcohol and zopiclone. Finally, 
some aspects of SH and apneas/hypopneas during alcohol and zopiclone influenced 
sleep in subjects with Overlap versus COPD only are discussed. 
 
5.1 Material and methods 
5.1.1 The study material and design 
To our knowledge, no studies of spontaneous sleep with PSG including ptcCO2 of as 
many as 100 normocapnic and hypercapnic COPD subjects have previously been 
published, nor are we aware of interventions with alcohol or zopiclone in groups of 
comparable numbers. As such, this study significantly contributes to the literature 
regarding nocturnal gas exchange in stable COPD. However, although effort was 
made in order to randomize the selection of the participants from the general COPD 
population and in designing the study, several aspects must be considered when 
interpreting the findings, and caution taken in generalizing the results.  
First, a possible selection bias prior to referral and admission must be addressed. 
Patients are referred to Glittreklinikken by pulmonary specialists and general 
practitioners from all parts of Norway and all applications are examined by 
pulmonary specialists at the clinic; patients with no previous history of attending IPR-
clinics are prioritized whereas admission may be refused to patients with diseases or 
conditions incompatible with IPR. Also, patients with very severe COPD and 
frequent exacerbations may be not being referred at all as their doctor might judge 
them unfit for lung rehabilitation. Likewise, there is a possibility of patients with 
primarily sleep related breathing problems not being referred of the same reason. 
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Second, as the waiting list for admission is long, failure of motivation is a drop-out 
cause as well as no-show due to acute illness or other reasons. Having CHRF implies 
an increased risk of COPD exacerbations and even death, thus reducing both the 
number of referred hypercapnic patients and the number of such inpatients eligible 
for participating in the study. In fact, we were not able to include the intended 60 
subjects in the CHRF group during the study period of 18 months, thus reducing the 
statistical power of the data. 
Third, due to lack of CHRF patients, these were not stratified for gender like the 
normocapnic subjects. Hence, only four of the 24 CHRF subjects were male. 
However, as the CHRF groups' median (interquartile range) age was as high as 68 
(15) years, the low percentage of males can be due to this genders' lower mean living 
age. In 2013 the expected living age in Norway was 83,6 years in females, 79,9 years 
in men, with COPD increasing mortality rates [111]. 
To sum up the considerations above, we believe our results regarding spontaneous 
sleep can be considered as representative for the cohort of stable COPD patients in 
Norway being motivated for pulmonary rehabilitation. However, we have missed the 
group having very frequent exacerbations that undoubtedly have more serious sleep 
respiratory disturbances than those described in this study. Also, having relatively 
few patients with CHRF makes the results regarding this subgroup vulnerable to type 
II statistical errors, as low statistical power reduces the probability of correctly 
rejecting a false null hypothesis. 
The open label study design (having no placebo group) in the alcohol and zopiclone 
interventions certainly can be a confounder. However, the knowledge of drinking 
alcohol or taking a sleeping pill will probably result in faster sleep onset and/or 
deeper sleep, and as shown in Paper I, the ptcCO2 increases with depth of sleep. Thus, 
as discussed in detail in paper II and III, we believe that not blinding patient or study 
personnel probably implied a more accentuated result regarding sleep 
hypoventilation. Importantly though, the sleep scorers were blinded to information 
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regarding control or interventional sleep, as such knowledge could interfere with their 
scoring. 
Finally, more detailed information on OSA-symptoms or alcohol consumption as 
discussed in the three papers and below (sections 5.1.3 and 5.2.3) would have 
increased the statistical power concerning the differences between COPD only and 
Overlap patients. As mentioned above, type II statistical errors must be considered 
with the low number of subjects in these subgroups. More participants in each group 
may have explained to more detail the differences regarding sleep architecture and 
hypoventilation in alcohol sleep.  
5.1.2 Blood gas measurements during sleep 
The gold standard for blood gas measurement is analyses of samples from arterial 
puncture. However, obtaining such material during sleep is difficult, as arterial 
sampling can disturb sleep and the number of samples is limited, with the risk of 
missing important gas pressure changes due to unstable respiration. Thus, surrogates 
are frequently used, as transcutaneous or end-tidal expiratory gas analysis of pCO2 
(ptcCO2 or petCO2, respectively), and oxygen saturation measurements by pulse 
oximetry (SpO2). In patients with COPD, petCO2  is considered too inaccurate to 
substitute for arterial pressure of carbon dioxide (paCO2) [112], whereas ptcCO2 has a 
lag-time compared to paCO2, and technical artifacts due to compression or loosening 
of the ptcCO2-measuring skin probe can occur. Likewise, reduced peripheral 
circulation or loosening of the SpO2-probe (e.g. from the finger tip) can result in too 
low values as compared to arterial oxygen saturation (SaO2). 
To overcome some of these challenges, a number of investigations were performed 
and precautions taken prior to data analysis (Supplementary material to Paper I, 
Appendix 7.2 and section 3.3.5).  
A small pilot study concluded with equivalence between changes in ptcCO2 and 
paCO2, whereas another clinical study showed a possible ptcCO2 measurement error 
between two TOSCA 500 devices of approximately 0.3 kPa. Thus, an individual pre-
sleep ptcCO2 value was calculated and the same device was utilized on both sleep 
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recordings from each patient. A third pilot study showed that a change in alveolar 
pCO2 (e.g. following an apnea or hypopnea) will result in arterial and transcutaneous 
pCO2 changes after approximately 10 seconds and one minute, respectively. Hence, 
to synchronize respiratory events recorded in the traces of nasal flow and thoracic and 
abdominal belt movements with the ptcCO2 trace, the latter was left-shifted 1 minute. 
To avoid compression from the pillow when the patient slept on the side, the ptcCO2-
probe was fixed to the patients' forehead rather than to the ear flip (figure 7 below and 
section 3.4.5). 
Finally, as the signal from the finger-probe was of poorer quality in some recordings, 
the SpO2-signal from the ptcCO2-probe fixed to the forehead was chosen for the SpO2-
calculations (section 3.5.3). 
5.1.3 Polysomnography 
For a full polysomnograpy, several sensors, electrodes, wires and belts are connected 
to the body, and this can obviously disturb sleep. Previous studies of consecutive 
PSG recordings has shown the first night's 
sleep to differ from the second night, 
however, the second and forthcoming nights 
can be expected to show similar results 
[107,108]. Thus, all patients slept an initial 
night for adaptation before recording of 
spontaneous or interventional sleep 
commenced in randomized order the second 
and third night. The synchronized 
measurements of ptcCO2 and SpO2 with the 
other PSG traces enabled a detailed 
assessment of the blood gases in the 
different stages of sleep during free 
breathing, apneas or hypopneas. 
Figure 7 Study patient with electrodes, belts and ptcCO2 probe on forehead. Private photo with permission 
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As discussed in the papers I-III, the high frequency of apneas/hypopneas was 
unexpected (27% having an AHI ≥15). As previous studies indicate a prevalence of 
OSA in COPD of only about 5% [113], our study was not designed for diagnosing 
OSA by collecting data on daytime sleepiness, loud snoring, witnessed breathing 
interruptions or awakenings due to gasping or choking. Such data would have 
enabled a diagnosis of OSA with an AHI ≥5, thus increased the number of patients in 
the Overlap and COPD only groups as described in the three papers. However, using 
AHI ≥15 regardless of symptoms is a conservative and not uncommonly used 
definition of OSA both in science and clinical practice. Due to a somewhat 
surprisingly high AHI's scored by the first polysomnographist, we decided to have all 
the recordings re-scored by a second polysomnographist. Both scorers were well 
experienced, working independent of each other and blinded to patient information 
except their gender, age, height and weight. As the results from these two scorers 
differed substantially both in sleep stage distribution and frequency of 
apneas/hypopneas, another two polysomnographists scored a random selection of 10 
PSG's, and the initial scorer having the best match to the latter two were finally 
selected for analyses. Concordance between the two controllers and the chosen initial 
polysomnographist was good (Paper I), so we believe the high prevalence of Overlap 
in this study is true, although it may not reflect the prevalence in the whole COPD 
population in Norway.  
 
5.2 Sleep hypoventilation and chronic hypercapnic 
respiratory failure 
5.2.1 Definition and prevalence of sleep hypoventilation 
In their papers from 2003 and 2011, respectively, O'Donoghue et al and Tarrega et al 
presented findings of sleep hypoventilation by slightly different definitions (section 
1.5.1), and they also defined daytime hypercapnia by different paCO2 cutoff values 
[52,53]. Thus, comparing results and judging prevalence is difficult. Not making this 
easier, the more recent AASM scoring rules defines sleep hypoventilation in two 
quite different ways [54]. Defining SH merely as having a pCO2 > 7.3 kPa for at least 
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10 minutes of sleep (AASM1) will include almost all patients with daytime CHRF, 
regardless of the degree of CO2 retention during sleep. The second definition 
(AASM2) is in our opinion a better one, as it is specific to phenomena occurring 
during sleep – by defining SH as a pCO2 increase of at least 1.3 kPa for ≥ 10 minutes 
to a value exceeding 6.7 kPa. Thus, the AASM2 definition was chosen in the analysis 
of data for paper I and II. However, at the request from a reviewer of paper III, the 
AASM1 definition was briefly mentioned, and values according to both definitions 
were stated in table 2 of paper III. As shown in this table, the number of patients with 
SH increased significantly in zopiclone sleep by both definitions, however, the SH 
scored individuals by the two definitions were not the same. Nevertheless, using the 
AASM1 definition would not have changed the fact that SH is highly prevalent in this 
population, nor the conclusion of SH being more frequent in zopiclone sleep 
compared to spontaneous sleep (paper III). 
In the analysis of spontaneous sleep in paper I (using the AASM2 definition), we 
found a SH prevalence of 15% in the whole study population. As indicated in figure 
3, only eleven of the 100 subjects in our study had CHRF and used LTOT, whereas 
SH was scored in six of these eleven patients (55%). Taken different SH and CHRF 
definitions into account, this prevalence is likely comparable to the results in previous 
studies, as O'Donoghue et al found sleep hypoventilation in 43% of their 56 stable 
COPD patients with CHRF using LTOT, whereas Tarrega et al reported a prevalence 
of 21% in 80 comparable subjects. 
5.2.2 SH as a predictor of CHRF? 
As shown in paper I, the regression model with the variables FEV1, use of LTOT and 
the maximal increase in ΔptcCO2, explains about half of the variation in daytime 
paCO2. Independently, the ΔptcCO2 increase explained only an additional 4%, after 
controlling for LTOT and FEV1. Thus, although the effect is weak, this finding 
supports the hypothesis of SH being a possible predictor of CHRF. We found the 
degree of hypoventilation to depend on the sleep stage; the highest Δp tcCO2 values 
being found in REM sleep. Also, as shown in figure 4, the SH-group had greater 
between-stage differences, indicating that these individuals are unable to increase 
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their ventilation and/or have less stringent CO2 homeostasis during sleep. For more 
than a decade, SH in COPD has been proposed to predict imminent CHRF as a 
consequence of impaired respiratory muscles, elevated resistive load and blunting of 
central chemoreceptors [114]. However, the fact that one third of our SH individuals 
were daytime normocapnic with only moderate COPD (figure 3), raises the question 
whether the SH phenomenon to some extent is independent of the failing respiratory 
pump in COPD. Subjects with congenital central hypoventilation syndrome (CCHS, 
also known as "Undines Curse", see preface) lack the central chemoreceptor control 
of breathing and seriously hypoventilate during NREM sleep, requiring ventilatory 
support to survive. Nevertheless, when awake, these individuals can breathe 
adequately by non-chemoreceptor inputs to the brain stem respiratory complex [115]. 
Sleep studies of normal individuals with arterial blood gases are few and small, and 
to our knowledge, the prevalence of SH according to the AASM definition is 
unknown. Thus, possibly, a reduced chemoreceptor function leading to SH - but not 
as serious as the rare condition of CCHS - can be found in individuals without COPD 
as well.  
To our knowledge, all previous studies of NIV in stable COPD were performed in 
subjects with established CHRF regardless of the degree of hypoventilation during 
sleep. The results of this treatment has been conflicting, however, a recent study has 
shown that adding NIV to standard treatment improves survival of patients with 
hypercapnic, stable COPD when NIV is targeted to greatly reduce daytime 
hypercapnia [70]. If SH really is predicting imminent hypercapnic respiratory failure, 
we suggest it should be considered as an indication for NIV by itself, independent of 
daytime paCO2.  In fact, some clinical centers have implemented this view. The 
German guidelines for non-invasive and invasive mechanical ventilation for 
treatment of chronic respiratory failure regard nocturnal hypercapnia as an 
independent indicator for the initiation of NIV in COPD patients [116]. Although 
these guidelines are based on consensus in expert conferences and relevant literature 
search, we have not found any studies reporting effects of this somewhat prophylactic 
treatment of CHRF, nor are we aware of planned studies of SH as an independent 
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indicator for NIV, with the aim to stop or delay the development of CHRF in stable 
COPD. 
5.2.3 SH due to alcohol and zopiclone 
As described in paper II, one of the consequences of giving a moderate dose of 
alcohol prior to sleep to a group of stable COPD-subjects is a very modest increase in 
the mean (SD) sleep ΔptcCO2 of 0.10 (0.25) kPa, and a decrease in the mean SpO2 of 
less than 1 %, whereas no blood gas changes are observed in the awake periods 
during the night. This alcohol induced, additional hypoventilation (coming on top of 
the "baseline" hypoventilation of each patient) occurs despite 3 % less REM sleep as 
percentage of TST – the sleep stage in which we have found the ΔptcCO2 to be 
greatest (paper I). From a clinical point of view, this sum up to that alcohol makes 
very small changes in blood gases and sleep architecture. However, although the 
study subjects were few, results from several subgroups diverged from the mean of 
the whole group, indicating that alcohol can have several effects on sleep architecture 
and the sleep respiratory drive to breathe, and also that COPD has several 
phenotypes. Approximately 1/3 of the subjects apparently had a beneficial effect of 
alcohol as the mean ΔptcCO2 decreased, maybe as a result of alcohols' bronco-
dilating properties [117].  Another quarter benefited of more REM sleep (often 
regarded as a sign of better sleep quality) with only a slight increase in the mean 
ΔptcCO2 (group 2 in figure 5). In paper II the possible explanation of this subgroups' 
increased REM sleep as alcohol abstinence is discussed, and we find it unlikely that 
one quarter of the study group had an undisclosed alcohol problem. However, the 
aspect of alcohol experience can be an issue, both in regard to less hypoventilation 
and increased REM sleep, as inexperienced drinkers tend to be sedated (more REM 
sleep) while experienced drinkers are stimulated (less REM sleep) following 
consumption of the same amount of alcohol [118]. Also, moderate doses of alcohol 
are known to improve sleep maintenance [77]. Regrettably, no record was made of 
sleep complaints or alcohol experience in our study subjects, however, teetotalers are 
not unusual in Norway, and insomnia is highly prevalent in COPD [85]. The number 
of patients with SH increased from 2 to 5 patients in baseline versus alcohol sleep, 
but this increase was clearly not statistically significant as one of the patients had SH 
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only during spontaneous sleep, not in alcohol sleep. However, type II statistical errors 
must be considered with such small numbers of study subjects, and as the mean 
ΔptcCO2 showed a slight increase, it is possible that alcohol in fact does increase the 
risk of SH. 
The subjects receiving 5 mg of the hypnotic zopiclone prior to sleep have an increase 
in the mean (SD) sleep ΔptcCO2 of approximately 0.22 (0.33) kPa; although not much 
from a clinical standpoint, this is about twice the increase of the alcohol-group. 
Importantly however, these two groups were not matched for age and blood gases, so 
differences between them must be viewed in this context; alcohol subjects versus 
zopiclone subjects having mean values of age 65.5 years versus  64.0 years, paO2 9.7 
kPa versus 9.1 kPa, and paCO2 5.1 kPa versus 5.5 kPa, respectively. As the mean 
sleep ΔptcCO2 in the zopiclone group increased in all sleep stages and – unlike the 
alcohol group - also during N0, zopiclone seems to be an agent of mild 
hypoventilation both in awake and sleeping individuals, unlike alcohol, at the doses 
used. This is also reflected in the number of subjects with SH increasing significantly 
in zopiclone sleep. However, no subgroup with lower mean ΔptcCO2 was found in 
zopiclone sleep; the reason can be that this drug does not have any impact on the 
bronchial muscle tonus (like that of alcohol).  
 
5.3 AHI changes due to alcohol and zopiclone in Overlap 
subjects 
Subgroups with Overlap showed somewhat different characteristics from the COPD 
only groups, both in alcohol and in zopiclone sleep. Importantly though; the study 
was not primarily designed or powered to study the difference in AHI between 
Overlap and COPD, so caution should be applied in interpreting these results. 
Paper III describes a significant drop in AHI when a subgroup of 11 Overlap patients 
was given 5 mg of the hypnotic zopiclone, a result in support of Eckert et al's findings 
in a group of OSA subjects [93]. A similar finding, although not as pronounced, is 
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shown in paper II; despite the average AHI not being changed by alcohol in the 
whole group of 26 subjects, a subgroup of six with Overlap (4 male) had lower mean 
values of AHI and ODI during alcohol sleep compared to control sleep. This result is 
in contrast to previous findings in asymptomatic and in snoring males, in mild to 
moderate OSA-males and in male, but not in female COPD patients 
[82,79,119,83,120]. However, we are not aware of studies of AHI change due to 
alcohol in Overlap subjects.  
The respiratory frequency increased during zopiclone N0 and NREM sleep, a result 
in line with Ranløv et al and Beaupre et al in their studies of normal subjects and of 
COPD patients [110,121]. Thus, although the respiratory frequency was not analyzed 
in alcohol sleep, a possible explanation for the reduced AHI both in zopiclone and 
alcohol sleep can be an increased respiratory frequency and correspondingly low tidal 
volumes, as well as altered arousal threshold. In alcohol sleep, bronco-dilatation and 
less mucus possibly can reduce the number of hypopneas as well. A recent meta-
analysis by Zhang et al including 448 patients with OSA found that non-
benzodiazepine hypnotics (including eszopiclone) improve sleep without worsening 
AHI and SpO2, suggesting OSA patients with insomnia indeed may benefit from such 
hypnotics [122]. 
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6 Conclusions and perspectives  
6.1 Paper I 
In this observational study of 100 (39 male) stable COPD patients with a mean FEV1 
1.1 L (42% of predicted), 15 on LTOT, 24 having CHRF (daytime paCO2 ≥ 6.3 kPa) 
we found that: 
x SH as defined by the AASM was more frequently found in subjects with 
CHRF compared to those with daytime normocapnia (38 % versus 8 % 
respectively), and a multiple regression model with the variables FEV1, LTOT 
and the maximal ptcCO2 increase during sleep explained 56 % of the variance 
in daytime paCO2 
 
x In subject without SH a pattern of gradual ptcCO2 increase from a pre sleep 
value (Δ ptcCO2) according to sleep stages was evident, with a mean (SD) 
increase from NREM to REM sleep of 0.20 (0.16) kPa, whereas this increase 
was 0.46 (0.28 kPa) in the SH subjects 
 
x No differences were discovered between the group of 27 subjects with Overlap 
(AHI ≥ 15) and the group of 25 subjects with COPD only (AHI < 5) in the 
daytime paCO2, sleep mean or max ΔptcCO2 or in the SH frequency, although 
the Overlap group had a lower minimum REM sleep SpO2 compared to the 
group of COPD only (median (IQR) 78 (19) % versus 87 (8) % respectively) 
 
6.2 Paper II 
In this randomized, un-blinded, crossover study of 26 (9 male) stable COPD subjects 
from the same cohort as paper I, 3 on LTOT and 4 having CHRF, we found that a 
moderate dose of alcohol (0.5 g ethanol/kg bodyweight) taken immediately prior to 
intended sleep results in: 
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x A decrease in the REM sleep percentage of TST, less awakenings and a minor 
increase in the mean ΔptcCO2, with mean differences (SD) 3 (7) %, 8 (13) 
awakenings and 0.10 (0.25) kPa, respectively 
 
 
x A minor drop in the mean (SD) SpO2 of 0.9 (2.1) % during NREM sleep, with 
no significant changes in REM sleep or during epochs awake after initial sleep 
onset (N0), nor in the frequency of oxygen desaturations (ODI) 
 
x No significant changes in AHI overall, however, subjects with Overlap tend to 
have fewer apneas/hypopneas in alcohol sleep 
 
x Alcohol induces changes in SpO2, but not in Δ ptcCO2, correlate with daytime 
paO2 and inversely with paCO2 (r = 0.5 and -0.6 respectively); thus patients 
with the greatest SpO2 changes in during sleep tend to have better daytime 
blood gas values compared to those with less desaturations  
 
6.3 Paper III 
In this randomized, un-blinded, crossover study of 31 (10 male) stable COPD 
subjects from the same cohort described in paper I, 7 on LTOT and 8 having CHRF, 
we have found that a pill of 5 mg zopiclone taken 30 min prior to intended sleep 
results in: 
x Nocturnal hypoventilation as a mean (SD) increase in the Δ ptcCO2 during N0, 
NREM and REM sleep of 0.14 (0.27) kPa, 0.22 (0.32) kPa and 0.25 (0.40) kPa 
respectively, and a doubled frequency of subjects with SH, however no 
significant changes in SpO2. 
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x No significant changes in AHI considering the whole group, however, Overlap 
subjects tend to have fewer apneas/hypopneas in zopiclone sleep compared to 
those with COPD only 
 
6.4 Clinical aspects and further research  
We have shown that an occasional, moderate dose of alcohol (e.g. two to three 
glasses of wine) does not gravely increase the risk of sleep hypoventilation in 
subjects with COPD, whereas a 5 mg pill of the hypnotic zopiclone improves sleep 
quality, however at the cost of an increase in the nocturnal ptcCO2 and an increased 
risk of SH. In subjects with Overlap however, both alcohol and zopiclone seem to 
reduce the number of apneas/hypopneas. Thus, from a clinical perspective it seems to 
be safe to give zopiclone to Overlap patients who - in the process of adaption to the 
CPAP mask - find it hard to sleep. 
The questions of whether SH really predicts imminent hypercapnic respiratory 
failure, to what extent the SH phenomenon is independent of the daytime homeostasis 
of pCO2, and ultimately, whether SH predicts death in COPD still remains to be 
answered. These answers are important in the selection of COPD patients to receive 
NIV; hence, sufficiently powered, randomized, prospective and longitudinal cohort 
studies of COPD patients with SH should be conducted. In addition to a diagnosis of 
CHRF, mortality should be an end point, due to the fact that CHRF is associated with 
increased mortality [14,15].  
Figure 8 indicates that the mean value of nocturnal ptcCO2 (including the N0 periods) 
only slightly underestimates the true sleep mean ptcCO2, as only 3% of study subjects 
had a mean sleep ptcCO2 – nocturnal sleep ptcCO2 difference > 0.25 kPa. Hence, as 
PSG is costly and time consuming, I suggest polygraphy (PG) with a trace for ptcCO2 
can be used as a SH screening tool for clinical purposes. In fact, a paper was quite 
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recently published describing this method in a study of SH in children with sleep 
disordered breathing [123]. 
Figure 8 Mean sleep versus mean nocturnal value of the transcutaneous carbon dioxide pressure increase (kPa) 
 
 
Note to figure 8: N=100 subjects, each represented by a dot. Nocturnal ptcCO2 includes periods awake after initial sleep 
onset (N0).  
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7 Appendix 
7.1 BODE index and MMRC 
The MMRC translation was presented at the annual meeting of the Norwegian Lung 
Medicine Society in the fall of 2010, and is now included in the National professional 
guidelines for prevention, diagnosis and follow-up of COPD provided by the 
Norwegian Directory of Health [124]. The MMRC version as presented in figure 9, 
and the BODE index derived from this score, are now routinely reported in the COPD 
patients' journal at Glittreklinikken. 
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Figure 9 Modified Medical Research Council Dyspnea Questionnaire, Norwegian version
 
Norsk versjon MMRC og beregning av BODE-index Side   : 1 av 1 
 
Kvalitetssystem for LHL Klinikkene - LHL-Klinikkene 
GKN3Kje.1.4.4.9 Norsk versjon MMRC og beregning av BODE-index 
 
MMRC  brukes som klassifikasjon av dyspnoe ved KOLS. Score på MMRC brukes også til å beregne BODE-
index. Dette er vist å være en god prognostisk indikator ved KOLS. Legene skal registrere MMRC i 
innkomstjournal på samtlige pasienter, ikke bare ved KOLS. Hos de som har KOLS skal MMRC også 
registreres ved utreise, og  BODE-index beregnes av legen på grunnlag av spirometri (beste FEV1), 6 min. 
gangtest ved utreise, MMRC-score ved utreise og BMI.  Bode-index dikteres i epikrise under supplerende 
undersøkelser. 
 
ID:       Dato: 
MMRC Norsk versjon (mai 2010, Glittreklinikken) 
Sett kun ett kryss ved beskrivelsen som passer best for deg 
 
0 Breathless only with strenuous exercise 
Jeg blir tungpustet bare når jeg trener hardt 
 
1 Short of breath when hurrying on the level or up a slight hill 
Jeg får åndenød når jeg skynder meg på flat mark eller i slakk motbakke 
 
2  Slower than most people of the same age on a level surface, or have to stop when walking 
at my own pace on the level 
Jeg er tregere enn den fleste på min alder på flat mark, eller jeg må stoppe på grunn av 
tungpust når jeg går i mitt eget tempo på flat mark 
 
3  Stop for breath walking 100 meters, or after walking a few minutes at my own pace on the 
level 
Jeg må stoppe for å få igjen pusten etter 100 meters gange, eller etter noen få minutter i 
mitt eget tempo på flat mark 
 
4        Too breathless to leave the house, or breathless when dressing or undressing 
Jeg er så tungpustet at jeg ikke kommer meg ut av huset, eller blir tungpust ved på- og 
avkledning 
 
Beregning av BODE-index: max score 10 
BODE poeng 0 1 2 3 Pasientscore: 
FEV1 (% av pred.) ≥65 50-64 36-49 ≤35  
6 min. gangtest (m) ≥350 250-349 150-249 ≤149  
MMRC score 0-1 2 3 4  
BMI >21 ≤21    
SUM  
Ref: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive 
pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12 
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7.2 PtcCO2 time delay 
Figure 10 Poster presented at the Amsterdam European Respiratory Society Congress 2011 
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8 Erratum 
The following errors were found after publishing of the papers; however, they did not 
influence the main results or the conclusions. 
 
1. Paper I, Supplementary material, Table S1, SES % for age group 60-69 years: 
The mean and SD results (reference values) is given as 86 (9.1) and 86 (7.9). 
Correct values are 86 (86) and 9.1 (7.9), respectively. 
 
2. Paper I, Supplementary material, section PtcCO2 delay time, last two 
sentences: 
The results showed a first response time (frt) meaning time from change in 
alveolar PCO2 to PtcCO2>2SD off stable phase as follows: Mean frt(SD) in 
increasing phase: 54(5,6) sec; Mean frt(SD) in decreasing phase: 57(15) sec. 
For arterial PCO2: 13,5(5,6) sec and 11,7(2,5) sec, accordingly. 
Correct:  
The results showed a first response time (frt) meaning time from change in 
alveolar PCO2 to PtcCO2>2SD off stable phase as follows: Mean frt(SD) in 
increasing phase: 54(18.1) sec; Mean frt(SD) in decreasing phase: 57(15) sec. 
For arterial PCO2: 13.5(5.6) sec and 11.7(2.5) sec, accordingly. 
 
3. Paper III, Discussion,  2.nd paragraph, 3.rd sentence: 
In 2007, Brander et al. studied nine males with advanced COPD…  
Correct: 
In 1992, Brander et al. studied nine males with advanced COPD…  
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